Genomatix met cash-flow break-even in 2003
Privately held Genomatix in Munich, Germany announced that it has met operational break-even in the year 2003. Genomatix is an in silico biology company with a unique edge in gene regulation. The company has developed a unique and strong technology platform of databases and software tools aimed at understanding gene and protein regulation at the molecular level. The idea was to drill down so deeply into genomics analysis that researchers and pharmaceutical industry could move well beyond observing transcriptional events to gain the insight to truly understand how the molecular mechanisms work. The technology has been systematically extended during the last five resulting in worldwide close to 15.000 researchers using it via the internet.
" We are very proud in having achieved this significant milestone in our corporate development, especially looking at last year's adverse business environment for platform technology providers", says Klaus J.W. May, Director Sales & Marketing.
"Based on our existing developments we will extend our lead by developing an ENCYCLOPEDIA OF GENE REGULATION, providing salient information for signaling and transcriptional pathways and networks not covered by conventional pathway databases", he continues.
"The cash-flow break-even very favorably positions Genomatix for a potential second round of financing. Additional capital allows for speeding up developments and broaden our reach. F.i. our unique capabilities in efficient experimental design for large-scale experimental verification of regulatory network components, or our proprietary technology for transcript-specific probe design. All this may well help to break the current grid-lock on microarray data interpretations. It will be based on an innovative chip design which, by no means, will be restricted to today's Genomatix proprietary applications", he closes.
Organizations
Other news from the department business & finance
These products might interest you

Limsophy by AAC Infotray
Optimise your laboratory processes with Limsophy LIMS
Seamless integration and process optimisation in laboratory data management

ERP-Software GUS-OS Suite by GUS
Holistic ERP solution for companies in the process industry
Integrate all departments for seamless collaboration

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Breakthrough at Ark opens way to reduce side-effects and increase efficacy of anti-cancer therapies - Unique DNA-based targeting technology Scavidin halts tumour progression with one-tenth of conventional chemotherapy dose
BioFocus and Almac collaborate to offer fluorescent lifetime assays
Genentech to set up Singapore's first Microbial-Based Biopharmaceutical Manufacturing Facility - Fourth Biologics Facility in Less Than 2 Years Helps Establish Singapore as a Serious Player in Biologics Manufacturing
Arakis completes Phase I trials of AD 337 in fibromyalgia syndrome
ABRAXANE meets primary endpoint in phase 3 trial for advanced non-small cell lung cancer
Oncolytics Biotech Inc. has been granted patent for extracting virus from cell culture
Researchers identify genes linked to chemoresistance
